Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$990K, compared with $284K a year earlier. Trailing-twelve-month accounts payables was -$793K. Over 3 fiscal years it compounded at -33.2% a year.
Context
- Accounts payables amounted to 1.6% of revenue in FY2025, down 9.4 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near -$990K or moves back toward the trailing-twelve-month quarterly average of -$198.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 481K USD
- Year-over-year change
- +119.4%
- 4-year CAGR
- +37.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 481K | +119.4% |
| FY2024 | 2024-12-31 | (2.48M) | -392.6% |
| FY2023 | 2023-12-31 | 846K | -47.6% |
| FY2022 | 2022-12-31 | 1.61M | +1095.6% |
| FY2021 | 2021-12-31 | 135K | — |
Accounts Payables vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 accounts payables of $793K is the 5th largest of the 11 companies compared; the peer median is $225.75K.
- Its year-over-year change of -49.2% is the 9th highest of 11, against a peer median of +94.4%.
- Accounts payables amounts to 2.8% of revenue for FHTX, versus a peer median of 4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.66M | +88.8% | +10.3% | 5.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $4.96M | -177.6% | — | — |
| LTM Mar 2026 | $2.19M | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | $2.14M | +288.2% | — | 15.5% | |
| LTM Mar 2026 | $793K | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $752K | +384.8% | — | 13.1% | |
| LTM Mar 2026 | $399K | +1230.0% | -34.4% | 0.6% | |
| LTM Mar 2026 | $254K | +71.6% | — | 0.4% | |
| LTM Mar 2026 | $197.49K | +121.5% | — | — | |
| LTM Mar 2026 | $42K | -102.6% | — | 2.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | +100.0% | — | — |
| Peer median (excluding FHTX) | $225.75K | +94.4% | -1.7% | 4.8% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Depreciation & Amortization | 3.23M | 7.9M | 3.45M | 3.12M | 3.33M |
| Deferred Income Tax | 1.41M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.38M | 0 | 16.19M | 11.89M | 10.4M |
| Change in Working Capital | 33.44M | 281.55M | (41.88M) | (32.27M) | (32.14M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | (3.17M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 135K | 1.61M | 846K | (2.48M) | 481K |
| Other Working Capital | 336.48M | (20.07M) | (42.73M) | (29.79M) | (32.62M) |
| Other Non-Cash Items | 4.61M | 13.05M | 2.56M | 3.47M | 6.59M |
| Operating Cash Flow | (50.25M) | 193.61M | (118.11M) | (100.41M) | (86.1M) |
| Capital Expenditures | (3.31M) | (1.21M) | (1.22M) | (906K) | (50K) |
| Acquisitions (Net) | (39.49M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.98M) | (409.35M) | (73.9M) | (261.47M) | (131.25M) |
| Sales of Investments | 139.47M | 166.23M | 219.58M | 232.47M | 243.34M |
| Other Investing Activities | 39.49M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 36.17M | (244.32M) | 144.45M | (29.9M) | 112.04M |
| Debt Repayment | (21.21M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 42.21M | 1.76M | 0 | 103.4M | 1.02M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.42M | 0 | 1.78M | 2.03M | 0 |
| Financing Cash Flow | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Effect of Forex Changes | 0 | 25K | 0 | 0 | 0 |
| Net Change in Cash | 8.34M | (48.92M) | 28.12M | (24.88M) | 26.96M |
| Free Cash Flow | (53.56M) | 192.4M | (119.33M) | (101.31M) | (86.15M) |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.